NASDAQ:ICCC ImmuCell (ICCC) Stock Price, News & Analysis $6.12 +0.02 (+0.33%) Closing price 04:00 PM EasternExtended Trading$6.17 +0.05 (+0.82%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ImmuCell Stock (NASDAQ:ICCC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ImmuCell alerts:Sign Up Key Stats Today's Range$6.12▼$6.1550-Day Range$5.90▼$7.6052-Week Range$3.34▼$7.60Volume3,086 shsAverage Volume19,515 shsMarket Capitalization$55.36 millionP/E Ratio32.21Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. Read More ImmuCell Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreICCC MarketRank™: ImmuCell scored higher than 12% of companies evaluated by MarketBeat, and ranked 907th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for ImmuCell. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmuCell is 32.21, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.69.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmuCell is 32.21, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 31.31.Price to Book Value per Share RatioImmuCell has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ImmuCell's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.21% of the float of ImmuCell has been sold short.Short Interest Ratio / Days to CoverImmuCell has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmuCell has recently decreased by 35.42%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmuCell does not currently pay a dividend.Dividend GrowthImmuCell does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.21% of the float of ImmuCell has been sold short.Short Interest Ratio / Days to CoverImmuCell has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmuCell has recently decreased by 35.42%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment1.07 News SentimentImmuCell has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ImmuCell this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ImmuCell insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.60% of the stock of ImmuCell is held by insiders.Percentage Held by InstitutionsOnly 13.47% of the stock of ImmuCell is held by institutions.Read more about ImmuCell's insider trading history. Receive ICCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ICCC Stock News HeadlinesWe Think That There Are Issues Underlying ImmuCell's (NASDAQ:ICCC) EarningsAugust 26 at 7:20 PM | finance.yahoo.comImmuCell Extends $1M Credit Line with BankAugust 25 at 4:48 PM | msn.comThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because there's a $15 fund tied directly to gold's surge that's still paying massive income… Up to 64% annually — with payouts every 30 days.August 28 at 2:00 AM | Investors Alley (Ad)ImmuCell Corp (ICCC) Q2 2025 Earnings Call Highlights: Strong Sales Growth and Margin Expansion ...August 19, 2025 | uk.finance.yahoo.comImmuCell Corporation (ICCC) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | seekingalpha.comImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025August 14, 2025 | globenewswire.comImmuCell Corporation: ImmuCell Announces Bank Debt RefinancingAugust 13, 2025 | finanznachrichten.deImmuCell Refinances Debt with Maine Community BankAugust 13, 2025 | msn.comSee More Headlines ICCC Stock Analysis - Frequently Asked Questions How have ICCC shares performed this year? ImmuCell's stock was trading at $5.15 at the start of the year. Since then, ICCC stock has increased by 18.8% and is now trading at $6.12. How were ImmuCell's earnings last quarter? ImmuCell Corporation (NASDAQ:ICCC) released its quarterly earnings results on Thursday, August, 14th. The biotechnology company reported $0.06 EPS for the quarter. The biotechnology company had revenue of $6.45 million for the quarter. ImmuCell had a trailing twelve-month return on equity of 6.25% and a net margin of 6.23%. Read the conference call transcript. Who are ImmuCell's major shareholders? Top institutional shareholders of ImmuCell include Geode Capital Management LLC (0.79%). View institutional ownership trends. How do I buy shares of ImmuCell? Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ImmuCell own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Altimmune (ALT), Biocept (BIOC), ImmunoGen (IMGN), Novavax (NVAX) and Pfizer (PFE). Company Calendar Last Earnings8/14/2025Today8/28/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ICCC CIK811641 Webwww.immucell.com Phone(207) 878-2770Fax207-878-2117Employees70Year Founded1982Profitability EPS (Trailing Twelve Months)$0.19 Trailing P/E Ratio32.11 Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.16 million Net Margins6.23% Pretax Margin6.27% Return on Equity6.25% Return on Assets3.87% Debt Debt-to-Equity Ratio0.28 Current Ratio3.85 Quick Ratio1.99 Sales & Book Value Annual Sales$28.27 million Price / Sales1.95 Cash Flow$0.06 per share Price / Cash Flow97.20 Book Value$3.30 per share Price / Book1.85Miscellaneous Outstanding Shares9,046,000Free Float8,539,000Market Cap$55.18 million OptionableNot Optionable Beta0.30 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:ICCC) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuCell Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuCell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.